AJ Vaccines is pleased to announce its collaboration with the Stop TB Partnership's Global Drug Facility (GDF), one of the world's leading procurement and supply mechanisms supporting tuberculosis programmes globally.
Tuberculosis (TB) remains one of the world's most significant infectious disease challenges, causing an estimated 1.25 million deaths annually. Through partnerships that help strengthen access to essential healthcare products, the global health community continues its efforts to reduce the burden of TB and move closer to the goal of ending the disease.
For decades, AJ Vaccines has been committed to addressing infectious diseases through the development, manufacturing and supply of vaccines and biological products. Building on this long-standing heritage, the collaboration with GDF reflects the company's continued dedication to supporting public health efforts and expanding access to healthcare solutions where they are needed most.
"At AJ Vaccines, we are proud to support initiatives that help strengthen access to healthcare products across diverse markets and healthcare systems," said Jens Als, Sales & Marketing Director at AJ Vaccines. "Collaborating with the Global Drug Facility is an important opportunity to contribute to global efforts against tuberculosis alongside highly respected partners in the international health community."
The collaboration also highlights AJ Vaccines' commitment to working with partners who share its ambition to address some of the world's most pressing infectious disease challenges.
"Tuberculosis continues to impact millions of people around the world every year," said Luis Charles Da Cruz Laranjeiro, Global Product Lead at AJ Vaccines. "We are pleased to support the Global Drug Facility's important work and contribute to efforts aimed at improving access to tools that support tuberculosis prevention and control."
As a company with deep roots in infectious disease prevention, AJ Vaccines remains committed to supporting global health through trusted partnerships, scientific expertise and reliable supply. The company looks forward to working alongside the Stop TB Partnership, the Global Drug Facility and the broader global health community in support of the shared ambition to reduce the burden of tuberculosis worldwide.